Wall Street expects Roivant Sciences to report consensus revenue of $3.68 million and an EPS of -$0.38, with the current stock price of $29.29 trading approximately 18% below the average analyst price target of $35.67.
Investors are primarily focused on the commercial trajectory of VTAMA cream and pivotal pipeline updates following the company's strategic refocus on autoimmune and immunology indications.
Recent momentum is driven by positive Phase 3 VALOR trial data for brepocitinib and clinical progress for the anti-FcRn antibody IMVT-1402, both of which are central to the company’s "Vant" valuation model.
Despite a projected widening of net losses, the company’s robust cash position of over $4.5 billion following the Moderna patent settlement provides a significant runway for upcoming clinical catalysts.